Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$35.22 - $51.88 $1.01 Million - $1.48 Million
-28,586 Reduced 45.98%
33,586 $1.41 Million
Q4 2023

Feb 14, 2024

SELL
$22.61 - $40.65 $570,269 - $1.03 Million
-25,222 Reduced 28.86%
62,172 $2.47 Million
Q3 2023

Nov 14, 2023

BUY
$25.45 - $37.46 $4,224 - $6,218
166 Added 0.19%
87,394 $2.41 Million
Q2 2023

Aug 14, 2023

BUY
$30.29 - $38.28 $177,559 - $224,397
5,862 Added 7.2%
87,228 $2.96 Million
Q1 2023

May 15, 2023

BUY
$34.78 - $47.43 $1,634 - $2,229
47 Added 0.06%
81,366 $2.93 Million
Q4 2022

Feb 14, 2023

SELL
$27.78 - $45.38 $861 - $1,406
-31 Reduced 0.04%
81,319 $3.62 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $1.29 Million - $2.14 Million
57,034 Added 234.55%
81,350 $2.29 Million
Q2 2022

Aug 10, 2022

SELL
$20.5 - $37.33 $4,120 - $7,503
-201 Reduced 0.82%
24,316 $656,000
Q1 2022

May 16, 2022

SELL
$27.64 - $39.32 $100,637 - $143,164
-3,641 Reduced 12.93%
24,517 $835,000
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $1 Million - $1.58 Million
28,158 New
28,158 $1.09 Million

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $987M
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.